Nordazepam

Revision as of 20:02, 8 April 2015 by Kiran Singh (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Nordazepam
Clinical data
Pregnancy
category
  • ?
Routes of
administration
Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability?
MetabolismHepatic
Elimination half-life50-120 hours
ExcretionRenal
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC15H11ClN2O
Molar mass270.71

WikiDoc Resources for Nordazepam

Articles

Most recent articles on Nordazepam

Most cited articles on Nordazepam

Review articles on Nordazepam

Articles on Nordazepam in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Nordazepam

Images of Nordazepam

Photos of Nordazepam

Podcasts & MP3s on Nordazepam

Videos on Nordazepam

Evidence Based Medicine

Cochrane Collaboration on Nordazepam

Bandolier on Nordazepam

TRIP on Nordazepam

Clinical Trials

Ongoing Trials on Nordazepam at Clinical Trials.gov

Trial results on Nordazepam

Clinical Trials on Nordazepam at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Nordazepam

NICE Guidance on Nordazepam

NHS PRODIGY Guidance

FDA on Nordazepam

CDC on Nordazepam

Books

Books on Nordazepam

News

Nordazepam in the news

Be alerted to news on Nordazepam

News trends on Nordazepam

Commentary

Blogs on Nordazepam

Definitions

Definitions of Nordazepam

Patient Resources / Community

Patient resources on Nordazepam

Discussion groups on Nordazepam

Patient Handouts on Nordazepam

Directions to Hospitals Treating Nordazepam

Risk calculators and risk factors for Nordazepam

Healthcare Provider Resources

Symptoms of Nordazepam

Causes & Risk Factors for Nordazepam

Diagnostic studies for Nordazepam

Treatment of Nordazepam

Continuing Medical Education (CME)

CME Programs on Nordazepam

International

Nordazepam en Espanol

Nordazepam en Francais

Business

Nordazepam in the Marketplace

Patents on Nordazepam

Experimental / Informatics

List of terms related to Nordazepam

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Nordazepam (marketed under brand names Stilny®, Madar®, Vegesan®, and Calmday®), also known as nordiazepam and desmethyldiazepam, is a 1,4-benzodiazepine derivative. Like other benzodiazepine derivatives, it has anticonvulsant, anxiolytic, muscle relaxant and sedative properties. However, it is used primarily in the treatment of anxiety. It is an active metabolite of diazepam, chlordiazepoxide, clorazepate, prazepam, and medazepam.[1]

Side effects

Common side effects of nordazepam include somnolence, which is more common in elderly patients and/or people on high dose regimens. Hypotonia, which is much less common, is also associated with high doses and/or old age.

Interactions

Benzodiazepines including N-desmethyldiazepam (nordazepam) may inhibit the glucuronidation of morphine leading to increased levels of and prolongation of the effects of morphine.[2]

Abuse

Nordazepam and other sedative hypnotic drugs are detected frequently in cases of people suspected of driving under the influence of drugs. Other benzodiazepines and zolpidem and zopiclone are also found in high numbers of suspected drugged drivers. Many drivers have blood levels far exceeding the therapeutic dose range suggesting a high degree of abuse potential for benzodiazepines and zolpidem and zopiclone.[3]

External links

References

  1. Biam. "NORDAZEPAM" (in French). Retrieved 18 October. Unknown parameter |refyear= ignored (help); Unknown parameter |accessyear= ignored (|access-date= suggested) (help); Check date values in: |accessdate= (help)
  2. Pacifici GM (1986). "Metabolic interaction between morphine and various benzodiazepines". Acta Pharmacol Toxicol (Copenh). 58 (4): 249–52. PMID 2872767. Unknown parameter |coauthors= ignored (help); Unknown parameter |month= ignored (help)
  3. Jones AW (2007). "Concentrations of scheduled prescription drugs in blood of impaired drivers: considerations for interpreting the results". Ther Drug Monit. 29 (2): 248–60. PMID 17417081. Unknown parameter |coauthors= ignored (help); Unknown parameter |month= ignored (help)

Template:Benzodiazepines Template:Anxiolytics


Template:Pharma-stub